NOVANIB T TAB

About

Novanib T Tablet likely contains Nintedanib, an oral tyrosine kinase inhibitor that targets multiple receptors, including vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), and platelet-derived growth factor receptor (PDGFR). By inhibiting these receptors, Nintedanib blocks the signaling pathways involved in the proliferation, migration, and differentiation of fibroblasts, which are key processes in the pathogenesis of fibrotic diseases.

Its primary therapeutic application is in the treatment of idiopathic pulmonary fibrosis (IPF) and other chronic fibrosing interstitial lung diseases with a progressive phenotype. Nintedanib works by slowing the progression of lung function decline, reducing the rate of acute exacerbations, and improving overall quality of life for patients. Its targeted action helps to mitigate the excessive deposition of extracellular matrix and scar tissue in the lungs, which characterizes these debilitating conditions.

Uses

• Treatment of idiopathic pulmonary fibrosis (IPF)
• Management of chronic fibrosing interstitial lung diseases
• Slowing the progression of lung function decline
• Reducing the risk of acute exacerbations in IPF

Directions For Use

Take one tablet orally twice daily, approximately 12 hours apart, with food, or as directed by your physician. Swallow the tablet whole; do not crush, chew, or break it.

Benefits

• Slows the progression of lung fibrosis
• Reduces decline in lung function
• Decreases frequency of acute exacerbations
• Improves quality of life for patients
• Targets multiple fibrotic pathways
• Offers a specific treatment for IPF

Side Effects

• Diarrhea
• Nausea
• Vomiting
• Abdominal pain
• Decreased appetite
• Weight loss
• Liver enzyme elevation
• Headache
• Hypertension
• Rash
• Bleeding events (rare)
• Arterial thromboembolic events (rare)

Safety Measures

• Alcohol - Avoid excessive alcohol consumption as it can increase the risk of liver enzyme elevations, a known side effect of Nintedanib.
• Pregnancy - Not recommended during pregnancy due to potential fetal harm. Use effective contraception during treatment and for at least 3 months after the last dose.
• Breastfeeding - Nintedanib is excreted in breast milk. Breastfeeding is not recommended during treatment due to potential harm to the infant.
• Liver - Use with caution in patients with mild liver impairment; not recommended for moderate or severe impairment. Liver function must be monitored regularly.
• Kidney - No dose adjustment is typically required for mild to moderate renal impairment. Use with caution in severe renal impairment due to limited data.
• Lung - Specifically used for lung fibrosis. However, monitor for worsening respiratory symptoms or new onset of interstitial lung disease.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.